National Academy of Inventors

Dr. Jon Weidanz, MPH, Ph.D., Joins BioNTX Board of Directors

Retrieved on: 
Monday, October 30, 2023
Knowledge, Sri Venkateswara College of Engineering, Research, Associate, MPH, Therapy, Biotechnology, Invention, National Academy of Inventors, College, UTA, Boehringer Ingelheim, National academy, Immunotherapy, University, Texas Tech University Health Sciences Center, Infection, Distinguishing, Moses Austin, Pharmaceutical industry

ARLINGTON, Texas, Oct. 30, 2023 /PRNewswire/ -- BioNTX , the bioscience and healthcare innovation trade organization in North Texas, is proud to announce the appointment of Jon Weidanz, MPH, Ph.D., as its newest member of the Board of Directors.

Key Points: 
  • ARLINGTON, Texas, Oct. 30, 2023 /PRNewswire/ -- BioNTX , the bioscience and healthcare innovation trade organization in North Texas, is proud to announce the appointment of Jon Weidanz, MPH, Ph.D., as its newest member of the Board of Directors.
  • His addition to the board underscores BioNTX's commitment to innovation and excellence in the biotechnology industry.
  • "I am excited and honored to join BioNTX and contribute to its mission of advancing healthcare through cutting-edge biotechnology," expressed Dr. Jon Weidanz.
  • BioNTX continues to demonstrate its commitment to attracting top-tier talent and expanding its capabilities to revolutionize healthcare and bioscience.

Regenerative Engineering Pioneer Professor Cato T. Laurencin Named 2023 Inventor of the Year

Retrieved on: 
Tuesday, August 15, 2023
University, Osteoarthritis, White House, CRISPR, National academy, IPO, Cato, National Academy of Engineering, COVID-19, Cancer, Chinese Academy of Engineering, University Professors Program, National Medal, Innovation, Cartilage, Celebration, Messenger, White, Regeneration, National Academy of Medicine, National Academy of Inventors, Invention, Royal Academy of Arts, Health, Nanotechnology, Pharmaceutical industry, Film industry, Science, Engineering, University of Connecticut

WASHINGTON, Aug. 15, 2023 /PRNewswire/ -- The Intellectual Property Owners Education Foundation (IPOEF) awards the prestigious Inventor of the Year award to Dr. Cato T. Laurencin for his groundbreaking innovation in regenerative engineering.

Key Points: 
  • WASHINGTON, Aug. 15, 2023 /PRNewswire/ -- The Intellectual Property Owners Education Foundation (IPOEF) awards the prestigious Inventor of the Year award to Dr. Cato T. Laurencin for his groundbreaking innovation in regenerative engineering.
  • Dr. Laurencin currently serves as one of two University Professors at the University of Connecticut and is the Chief Executive Officer of The Cato T. Laurencin Institute for Regenerative Engineering at UConn.
  • Professor Laurencin's innovations in regenerative engineering and his impact on the fields of biomaterials, nanotechnology, and stem cell science have had immeasurable impact.
  • Dr. Laurencin will be presented the 2023 IPO Education Foundation Inventor of the Year award at the 2023 IPOEF Awards Celebration on December 6, 2023, in Washington, DC.

Asep Inc. Founder, Chair and CEO, Dr. Robert E. W. Hancock, Ranked 4th Best Microbiologist in the World

Retrieved on: 
Tuesday, June 20, 2023
Plan, ASEP, CSE, RSU, Canadian Securities Exchange, Sepsis, Share (finance), Quality of life, FSE, NAI, Research, Sale, Invention, Asep, National academy, Publication, Option, National Academy of Inventors, SEDAR, Fellow, Economic development, Knowledge, Diagnosis, News, Chair, Pharmaceutical industry

In addition to the research.com honour, Dr. Hancock was also installed as a Fellow of the National Academy of Inventors (NAI) based in Tampa, Florida.

Key Points: 
  • In addition to the research.com honour, Dr. Hancock was also installed as a Fellow of the National Academy of Inventors (NAI) based in Tampa, Florida.
  • Dr. Hancock will be travelling to Washington, DC, on June 25, 2023, to accept his Fellowship at the NAI's annual meeting.
  • The Company's COO, Tim Murphy, commented, "The Asep board and team would like to congratulate Dr. Hancock for these prestigious honours.
  • Asep Inc. is very pleased to announce the addition of Louise Rose Pacini to the Company's advisory board, effective June 6, 2023.

The Dreyfus Prize in the Chemical Sciences Winner Announced

Retrieved on: 
Friday, May 12, 2023
Research, Biotechnology, Other Education, Radiology, Collegiate, Consumer, Health, Science, Education, Other Science, Dreyfus Prize in the Chemical Sciences, Neuron, National academy, University of Chicago, Chemistry, Pritzker School, University of the Chinese Academy of Sciences, Harvard University, European Molecular Biology Organization, Breakthrough Prize in Life Sciences, Dean, Howard Hughes Medical Institute, American Academy, The Camille and Henry Dreyfus Foundation, Biomedical sciences, Multimedia, Brain, Cell, RNA, MacArthur Fellows Program, Biochemistry, Neuroscience, Chemical substance, Vilcek Foundation, National Academy of Medicine, European, University, Heineken Prizes, National Academy of Inventors, Biology, Pearl Meister Greengard Prize, L'Oréal-UNESCO For Women in Science Awards, American Philosophical Society, Genome, Breakthrough Prize, Pharmaceutical industry, Microscope, Medicine, Imaging, Biophysics

Professor of Science, Harvard University, is the recipient of the 2023 Dreyfus Prize in the Chemical Sciences.

Key Points: 
  • Professor of Science, Harvard University, is the recipient of the 2023 Dreyfus Prize in the Chemical Sciences.
  • The international biennial Prize, which includes a $250,000 award, is conferred this year in Imaging in the Chemical Sciences.
  • View the full release here: https://www.businesswire.com/news/home/20230511005909/en/
    Xiaowei Zhuang of Harvard University announced as recipient of the 2023 Dreyfus Prize in the Chemical Sciences (Photo: Business Wire)
    Zhuang receives this top honor for her pivotal contributions to Imaging in the Chemical Sciences.
  • I would like to thank the Camille and Henry Dreyfus Foundation for being a leading supporter of the chemical sciences community for over 75 years.”
    The Dreyfus Prize in the Chemical Sciences, initiated in 2009, is conferred in a specific area of chemistry each cycle.

2022 Top 100 Worldwide University Patent Holders Announced by National Academy of Inventors

Retrieved on: 
Wednesday, April 26, 2023
Patent, Intellectual property, United States Patent and Trademark Office, Calendar, University, Research, NAI, Under Secretary of Commerce for Intellectual Property, World Intellectual Property Day, National academy, National Academy of Inventors, Annual general meeting, Invention, Annual report, Commerce, Pharmaceutical industry

TAMPA, Fla., April 26, 2023 /PRNewswire/ -- In celebration of World IP Day, the National Academy of Inventors (NAI) will release its annual list of the Top 100 worldwide university utility patent holders on April 26th.

Key Points: 
  • TAMPA, Fla., April 26, 2023 /PRNewswire/ -- In celebration of World IP Day, the National Academy of Inventors (NAI) will release its annual list of the Top 100 worldwide university utility patent holders on April 26th.
  • The Academy has been releasing the rankings based on calendar year data provided by the United States Patent and Trademark Office since 2013.
  • "Throughout its existence, the National Academy of Inventors has sought to quantify with hard data, the vital role research and patented technology developed at academic institutions play in our society", Dr. Paul Sanberg, President of the Academy noted.
  • In a change from past practice, the Academy has updated the requirements for the Top 100 placement to include all named inventors listed on the patent to provide a more comprehensive view of the patents held by these universities.

Sisu Pharma Welcomes Renowned Prostate Cancer Drug Developer Professor Michael Jung to its Scientific Advisory Board

Retrieved on: 
Thursday, April 20, 2023
Pharma, Drug development, University, Prostate cancer, Coronavirus Scientific Advisory Board, Science, Biochemistry, National academy, HSF1, Invention, National Academy of Inventors, Walter, Drug discovery, UCLA, FDA, Disease, Pharmaceutical industry, Sisu, Chemistry

SAN DIEGO, April 20, 2023 /PRNewswire-PRWeb/ -- Sisu Pharma, a biotech company exploiting cellular stress to treat therapy-resistant cancers, is delighted to announce that Professor Michael Jung has joined its Scientific Advisory Board. A highly accomplished scientist and scholar, Professor Jung brings a wealth of experience in medicinal chemistry and drug discovery to the Sisu team, with a particular focus on prostate cancer drug development. He is the inventor of both Xtandi and Erleada, FDA approved small molecule therapies that revolutionized the treatment of castration-resistant prostate cancer, an especially lethal form of the disease.

Key Points: 
  • A highly accomplished scientist and scholar, Professor Jung brings a wealth of experience in medicinal chemistry and drug discovery to the Sisu team, with a particular focus on prostate cancer drug development.
  • "I am excited to be part of Sisu Pharma's Scientific Advisory Board and to collaborate with their talented team," said Professor Jung.
  • As a member of the Scientific Advisory Board, Professor Jung will provide strategic guidance and counsel to Sisu Pharma's research and development team.
  • "We are thrilled to welcome Professor Jung to our Scientific Advisory Board", said Sean O'Brien, CEO of Sisu Pharma.

Jeff Karp, Ph.D., Joins Eterna’s Scientific Advisory Board

Retrieved on: 
Tuesday, March 28, 2023
Popular Mechanics, Medicine, Society, Broad Institute, Canadian Academy of Engineering, European Society for Biomaterials, Royal Society of Chemistry, Boston Business Journal, Research, Messenger, Biology, Harvard Medical School, MIT Technology Review, National academy, Biomedicine, Patient, ERNA, Outline of health sciences, National Academy of Inventors, Boston (magazine), Hospital, Applied science, BMES, Biomedical Engineering Society, American Institute, Distinguishing, Mechanics, Vaccine, Pharmaceutical industry, Eterna, Engineering, Anesthesia, Brigham

CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the appointment of Jeff Karp, Ph.D. to Eterna’s Scientific Advisory Board.

Key Points: 
  • Matt Angel, Ph.D., Chief Executive Officer and President of Eterna, commented, “Jeff is a world-class expert in drug delivery and cell therapeutics with a successful track record as an entrepreneur whose innovations have spurred numerous biomedical products and companies.
  • Several technologies developed in his lab have led to multiple products currently in development or on the market, and to the launch of ten companies.
  • Most recently, he received the Clemson Award for Applied Research, the highest award for innovation from the Society for Biomaterials.
  • His work has been selected by Popular Mechanics as one of the Top 20 New Biotech Breakthroughs that Will Change Medicine.

Tomorrow Health Adds Former Cleveland Clinic CEO Dr. Toby Cosgrove to Advisory Board

Retrieved on: 
Tuesday, January 31, 2023
NEXT Woman of the Year awards, Thorax, United States Department of Health and Human Services, Public service, Advisory board, Cleveland Clinic, History of Cleveland Clinic, The Advisory Board Company, National Academy of Medicine, National Academy of Inventors, Human services, CMO, Cleveland, Bain, Advisory, Bain & Company, Workflow, Patient, National academy, Nursing, Health

Former Cleveland Clinic CEO and President joins the advisory board as the company continues to scale its delivery of exceptional home-based care to millions of patients.

Key Points: 
  • Former Cleveland Clinic CEO and President joins the advisory board as the company continues to scale its delivery of exceptional home-based care to millions of patients.
  • NEW YORK, Jan. 31, 2023 /PRNewswire/ -- Tomorrow Health , a home-based care company, today announced the addition of Dr. Toby Cosgrove to its Advisory Board.
  • At Tomorrow Health, we seamlessly connect patients, providers, health plans, and suppliers to deliver quality home-based care and drive down costs," said Vijay Kedar, co-founder and CEO of Tomorrow Health.
  • "We're thrilled for Dr. Cosgrove to join our advisory board as we work together to restore the home as the primary place of care."

Piezo Therapeutics Launches to Transform Delivery of Nucleic Acid Medicines

Retrieved on: 
Thursday, January 19, 2023
Gene expression, VentureLab, COVID, Global health, Therapy, COVID-19, RNA transfection, Open philanthropy (doctrine), DNA, Safety, Science Publishing Group, Vaccine, Drug development, Partnership, Engineering, Georgia Tech Research Institute, Regent, RNA, National Academy of Inventors, Sundell, National academy, Medical device, Management, Pharmaceutical industry, Piezo, Georgia Tech

ATLANTA, Jan. 19, 2023 /PRNewswire-PRWeb/ -- Piezo Therapeutics launched with $2 million in seed funding from Open Philanthropy to develop its platform: a simple and affordable way of delivering RNA and DNA medicines, including vaccines and therapeutic proteins. Piezo's platform combines electric pulses and microneedles to deliver nucleic acid medicines safely and efficiently while accelerating manufacturing, easing access, and minimizing costs.

Key Points: 
  • Piezo is developing a simple, affordable, and scalable platform designed for rapid, safe, and efficient delivery of nucleic acid medicines, including RNA/DNA vaccines, therapeutic proteins, and dermal gene therapies.
  • Invented by Georgia Tech researchers, Piezo launches with $2 million in seed funding from Open Philanthropy.
  • Piezo's platform combines electric pulses and microneedles to deliver nucleic acid medicines safely and efficiently while accelerating manufacturing, easing access, and minimizing costs.
  • While this platform has high applicability for vaccines (Piezo's immediate focus), it is designed for a broad array of nucleic acid therapeutics.

Asep Medical Holdings Inc. to Hold Important Investor Information Webinar on January 24, 2023

Retrieved on: 
Wednesday, January 18, 2023
EST, CSE, FSE, Kingdom, ASEP, CSO, Patient, DC, National Academy of Inventors, Acquisition, Columbia Senior Executive Program, Interest, National academy

Webinar Features Strategic Insights from Asep Inc.'s Senior Executives, including Founder and CEO Dr. Robert E. W. Hancock, CSO Dr. Evan Haney and COO Mr. Timothy Murphy

Key Points: 
  • Webinar Features Strategic Insights from Asep Inc.'s Senior Executives, including Founder and CEO Dr. Robert E. W. Hancock, CSO Dr. Evan Haney and COO Mr. Timothy Murphy
    VANCOUVER, BC, Jan. 18, 2023 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce that it is holding an online webinar on January 24, 2023, at 1:00 pm EST to provide essential and exciting updates on the company's global market developments, scientific advances and investment-related milestones.
  • Interested parties are invited to register for the webinar ( here ) to discover historical milestones and the Company's concrete plans for the future.
  • Members of Asep Inc.'s executive team will present information and answer questions from attendees on the following,—
    Updates on the company's recent acquisition of medical instruments innovator SafeCoat Medical Inc.
  • Exciting information on a joint venture definitive agreement signed with the Kingdom of Bahrain and its healthcare investment firm, Seaspring W.L.L.